Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

360
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

699
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
699
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

675
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
675
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

859
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
859

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TBI-associated acute lung injury is associated with downregulation of miRNA-362.

The journal of trauma and acute care surgery·2026
Same author

Case Report: Idiopathic Wunderlich syndrome complicated by a perinephric abscess with fistula formation to the descending colon.

Frontiers in medicine·2026
Same author

Exacerbation-related burden in patients with severe asthma in South Korea: a population-based cohort study.

BMJ open respiratory research·2026
Same author

Associated factors of osteoporosis and the impact of osteoporosis on all-cause mortality in incident hemodialysis older patients.

Kidney research and clinical practice·2025
Same author

Zileuton Attenuates Acute Kidney Injury in Glycerol-Induced Rhabdomyolysis by Regulating Myeloid-Derived Suppressor Cells in Mice.

International journal of molecular sciences·2025
Same author

Regulated Release of Small Extracellular Vesicles Directs Neutrophil Recruitment in Cutaneous Wound Healing.

The Journal of investigative dermatology·2025

Related Experiment Video

Updated: May 6, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
04:36

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

2.3K

Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in

Yeo-Jin Kang1, Eun Jin Bae, Kyungo Hwang

  • 1Department of Internal Medicine, School of Medicine Gyeongsang University, 816 Beongil 15 Jinju-daero, Jinju, Gyeongnam South Korea.

Springerplus
|October 25, 2013
PubMed
Summary
This summary is machine-generated.

Terlipressin treatment can cause a drop in serum sodium levels, especially in patients with liver cirrhosis. The initial serum sodium level is the most significant factor predicting this decrease.

Keywords:
HyponatremiaLiver cirrhosisTerlipressin

More Related Videos

Surgical Procedures for a Rat Model of Partial Orthotopic Liver Transplantation with Hepatic Arterial Reconstruction
18:47

Surgical Procedures for a Rat Model of Partial Orthotopic Liver Transplantation with Hepatic Arterial Reconstruction

Published on: March 7, 2013

40.2K
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

11.0K

Related Experiment Videos

Last Updated: May 6, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
04:36

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

2.3K
Surgical Procedures for a Rat Model of Partial Orthotopic Liver Transplantation with Hepatic Arterial Reconstruction
18:47

Surgical Procedures for a Rat Model of Partial Orthotopic Liver Transplantation with Hepatic Arterial Reconstruction

Published on: March 7, 2013

40.2K
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

11.0K

Area of Science:

  • Hepatology
  • Nephrology
  • Clinical Pharmacology

Background:

  • Terlipressin, a vasopressin prodrug, affects V1 and V2 receptors.
  • Its impact on serum sodium concentration in liver cirrhosis patients remains debated.

Purpose of the Study:

  • To determine the incidence of decreased serum sodium levels after terlipressin administration in liver cirrhosis patients.
  • To identify risk factors associated with this hyponatremia.

Main Methods:

  • Retrospective analysis of 127 liver cirrhosis patients.
  • Examined serum sodium levels before and after terlipressin treatment.
  • Univariate and multivariate analyses to identify risk factors.

Main Results:

  • Serum sodium decreased significantly (P < 0.001) in all patients.
  • 35.4% experienced a decrease >5 mmol/L; 12.6% experienced a decrease >10 mmol/L.
  • Initial serum sodium level was the strongest predictor of sodium reduction.

Conclusions:

  • Acute reduction in serum sodium is common with terlipressin.
  • Baseline serum sodium level is a key determinant of terlipressin-induced hyponatremia.